Discovering new treatments, unlocking possibilities

Evommune is a clinical stage, biotechnology company dedicated to the development of transformative medicines for inflammatory diseases

By leveraging our innovative tissue-based approach, we can accelerate discovery of novel therapies and better predict clinical outcomes

Millions struggle with inflammatory conditions

60% of Americans live with chronic inflammatory diseases, and it is expected that the prevalence will increase steadily over the next 30 years.1

Chronic inflammatory diseases are the most significant cause of death in the world, and those who live with them have a reduced quality of life.1

Evommune’s focus is the discovery and development of unique therapies that help patients with chronic inflammatory diseases.

Reference: 1. Pahwa R, Goyal A, Bansal P, et al. Chronic Inflammation. StatPearls Publishing. 2020. Published January 2020. Updated August 10, 2020. Accessed October 7, 2020.

Our Approach

Evommune utilizes a novel screening platform to identify molecules that are differentiated and that have a greater probability of being effective in treating patients with immune-mediated inflammatory diseases.


By recognizing the interdependence of innovation and sustainable healthcare, we strive to develop unique medicines that benefit the patient and deliver significant value.


We utilize a tissue-based screening platform, developed by Evommune scientists, to efficiently evaluate development candidates that have the potential to meet our profile for differentiation. This approach greatly enhances the probability of selecting new molecules that are clinically effective.


Our highly accomplished team and extensive research and development experience allows us to accelerate each phase of the drug development process. We have a 30-year track record of small molecule and biologic regulatory approvals across multiple therapeutic areas.


Program Target Route Discovery Pre-IND Phase 1 Phase 2 Phase 3 Commercial Rights
EVO101 IRAK4 Topical
Atopic Dermatitis
EVO102 RORγt Topical
EVO104 PKCϴ Oral
Rheumatoid Arthritis
Atopic Dermatitis
Program EVO101
Target IRAK4
Route Oral
Phase Phase 1
Commercial Rights World-wide
Program EVO102
Target RORγt
Route Topical
Phase Pre-IND
Commercial Rights World-wide
Program EVO103
Target MRGPRX2
Route Oral
Phase Discovery
Commercial Rights World-wide
Program EVO104
Target PKCϴ
Route Oral
Phase Discovery
Commercial Rights World-wide





Science-Based Team

Our team has a track record of drug approvals and commercial successes. At Evommune, we are building off our extensive experience to connect disciplines that address inflammatory disease. Our dedication to science and innovation drives us in our pursuit to identify, discover, and develop unique and vital medicines.

“Available medicines have made progress treating inflammation, but we know there’s a need for safer, more effective therapies. That’s where Evommune will make a difference—we are committed to science and innovation to improve patients' lives.”

Luis Peña

President & CEO, Evommune


Luis Peña

President & CEO

Eugene A. Bauer, MD

Chief Medical Officer

Kyle Carver, MBA, CPA

Chief Financial Officer

Gregory S. Moss, Esq.

Chief Corporate Strategy & Legal Officer; Corporate Secretary & Chief Compliance Officer

Janice Drew, MPH

Senior Vice President, Product Development

Hans Hofland, PhD

Senior Vice President, Research

Lou Sehl, PhD

Senior Vice President, Technical Operations

Board of Directors

Luis Peña

President & CEO

Eugene A. Bauer, MD

Chief Medical Officer

David E. Cohen, MD, MPH

Charles C. and Dorothea E. Harris Professor of Dermatology, Vice Chairman of Clinical Affairs, Chief of Allergy and Contact Dermatitis, and Director of Occupational and Environmental Dermatology

Rob Hopfner, RPh, PhD, MBA

Managing Partner at Pivotal bioVenture Partners

Benjamin F. McGraw, III

Chairman and Chief Executive Officer at TheraVida, Inc.

Gilles Nobécourt

Partner at Andera Partners

Felice Verduyn-van Weegen

Partner at LSP

Scientific Advisors

Russ B. Altman, MD, PhD

Kenneth Fong Professor of Bioengineering, Genetics, Medicine, Biomedical Data Science and, by courtesy, Computer Science, Stanford University

Brian Berman, MD, PhD

Professor Emeritus, Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine

James Q. Del Rosso, DO

Adjunct Clinical Professor (Dermatology), Touro University Nevada

Emma Guttman-Yassky, MD, PhD

Sol and Clara Kest Professor of Dermatology and Immunology, Icahn School of Medicine at Mount Sinai

James G. Krueger, MD, PhD

Professor, Laboratory Head, The Rockefeller University

Mark G. Lebwohl, MD

Waldman Professor and Chairman, Kimberly and Eric J. Waldman Department of Dermatology, Dean for Clinical Therapeutics, Icahn School of Medicine at Mount Sinai

Dan R. Littman, MD, PhD

Helen L. and Martin S. Kimmel Professor of Molecular Immunology at the Skirball Institute of Biomolecular Medicine of NYU Langone Medical Center and Investigator of the Howard Hughes Medical lnstitute

Georg Stingl, MD

Professor Emeritus, Department of Dermatology, Medical University of Vienna


We are dedicated to establishing partnerships that support our strategy to drive an innovative development pipeline leading to novel treatments that improve the lives of patients with inflammatory conditions.

We look for the best in our partners, collaborating with those we know will inspire us to achieve greater success together. We are continually evaluating new opportunities and will pursue products from discovery through clinical-stage development.

Contact us to discuss a partnership at:

Axcelead Logo

Axcelead is the first integrated drug discovery solutions provider in the pharmaceutical industry in Japan, having succeeded the drug discovery research capabilities of Takeda Pharmaceutical Company Limited and started its business on July 1, 2017. The company provides integrated services, from discovery of drug targets to optimization of small- and medium-molecule drug candidates, in which the company has particular expertise, and to the process of bridging the gap to clinical development.

Dermira Logo

Dermira, a wholly-owned subsidiary of Eli Lilly and Company, is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology. We are focused on delivering important new therapies to the millions of patients living with chronic skin conditions.

Dermira is committed to understanding and addressing the needs of both patients and physicians. We are using our experience and insight to identify and develop leading-edge medical dermatology clinical programs. Our goal is to help transform the way skin conditions are treated by serving as the bridge between unmet patient needs and the significant scientific advances being made in understanding skin biology.

Join Our

At Evommune, we are passionate about our mission to help people with inflammatory diseases. We believe in integrity and personal accountability—qualities that make us good team members, partners, and collaborators. We work hard and take satisfaction in doing it right every time.

We protect our culture and core values. We are:

Collaborative Passionate Open Committed Fun

We value individuals who are not only talented at what they do, but also are meticulous about how they do it. Do you have deep knowledge of your function and have strong emotional intelligence? Are you a professional who is an expert in your field and is ready to share your passion? Do you value relationships and the success of your colleagues? If so, reach out to us to discuss working here.

Evommune is an Equal Opportunity Employer and does not discriminate on the basis of race, religion, color, sex, gender identity, sexual orientation, age, nondisqualifying physical or mental disability, national origin, veteran status, or any other characteristic protected by applicable law.

Open Positions

Evommune is a biopharmaceutical company focused on the discovery and development of unique therapies that help patients with chronic inflammatory diseases. We are taking a tissue-based approach to advance insights and accelerate the development of transformative medicines for inflammatory diseases. Interested candidates should send their resume to